Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front-line Treatment With Other Tyrosine Kinase Inhibitors
Latest Information Update: 06 Feb 2023
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms BEST
- 02 Feb 2023 Status changed from active, no longer recruiting to completed.
- 17 Jun 2022 Results presented at the 27th Congress of the European Haematology Association
- 04 Jan 2022 Planned End Date changed from 1 Nov 2021 to 1 Apr 2022.